论文部分内容阅读
目的探讨多发性骨髓瘤患者血清白细胞介素18(IL-18)和可溶性血管细胞黏附分子-1(sVCAM-1)的水平及临床意义。方法应用ELISA法检查15例多发性骨髓瘤患者治疗前的血清IL-18和sVCAM-1的水平,并与正常对照进行比较。结果多发性骨髓瘤患者血清IL-18和sVCAM-1的水平[(1154.6±299)pg/ml和(1704.5±405.86)ng/ml]明显高于正常对照组[(256.39±59)pg/ml和(538.16±91.21)ng/ml]。结论多发性骨髓瘤患者血清IL-18、sVCAM-1含量明显增高,可能与多发性骨髓瘤的发病机制有关。
Objective To investigate the levels and clinical significance of serum interleukin 18 (IL-18) and soluble vascular cell adhesion molecule-1 (sVCAM-1) in patients with multiple myeloma. Methods The levels of serum IL-18 and sVCAM-1 in 15 patients with multiple myeloma before treatment were detected by ELISA and compared with the normal control. Results Serum levels of IL-18 and sVCAM-1 in patients with multiple myeloma [(1154.6 ± 299) pg / ml and (1704.5 ± 405.86) ng / ml] were significantly higher than those in the normal control [(256.39 ± 59) pg / ml And (538.16 ± 91.21) ng / ml]. Conclusion Serum levels of IL-18 and sVCAM-1 are significantly increased in patients with multiple myeloma, which may be related to the pathogenesis of multiple myeloma.